Anna David is Director of the Elizabeth Garrett Anderson Institute for Women’s Health at University College London (UCL) in London and a Consultant in Obstetrics and Maternal Fetal Medicine at UCL Hospital. Clinically she specializes in fetal medicine, severe congenital disease, fetal growth restriction and prevention of preterm birth. Her research team is developing novel prenatal genomic medicines using stem cells and gene therapy. She led an international consensus to develop the first terminology to define and grade maternal and fetal adverse events for clinical trials in pregnancy: MFAET. She has also co-developed lactation adverse event terminology.
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.
